JP7508048B2 - 細胞外小胞の分泌を促進するための組成物 - Google Patents

細胞外小胞の分泌を促進するための組成物 Download PDF

Info

Publication number
JP7508048B2
JP7508048B2 JP2021512320A JP2021512320A JP7508048B2 JP 7508048 B2 JP7508048 B2 JP 7508048B2 JP 2021512320 A JP2021512320 A JP 2021512320A JP 2021512320 A JP2021512320 A JP 2021512320A JP 7508048 B2 JP7508048 B2 JP 7508048B2
Authority
JP
Japan
Prior art keywords
cells
extracellular vesicles
compound
composition
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512320A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020204161A5 (https=
JPWO2020204161A1 (https=
Inventor
一隆 的場
克彦 木田
泰斗 西野
力成 華山
孟史 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanazawa University NUC
Nissan Chemical Corp
Original Assignee
Kanazawa University NUC
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanazawa University NUC, Nissan Chemical Corp filed Critical Kanazawa University NUC
Publication of JPWO2020204161A1 publication Critical patent/JPWO2020204161A1/ja
Publication of JPWO2020204161A5 publication Critical patent/JPWO2020204161A5/ja
Application granted granted Critical
Publication of JP7508048B2 publication Critical patent/JP7508048B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/562—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom
    • C07C45/565—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom by reaction with hexamethylene-tetramine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021512320A 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物 Active JP7508048B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019071759 2019-04-04
JP2019071759 2019-04-04
PCT/JP2020/015310 WO2020204161A1 (ja) 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物

Publications (3)

Publication Number Publication Date
JPWO2020204161A1 JPWO2020204161A1 (https=) 2020-10-08
JPWO2020204161A5 JPWO2020204161A5 (https=) 2023-03-17
JP7508048B2 true JP7508048B2 (ja) 2024-07-01

Family

ID=72669110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512320A Active JP7508048B2 (ja) 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物

Country Status (4)

Country Link
US (1) US20220162561A1 (https=)
EP (1) EP3950060A4 (https=)
JP (1) JP7508048B2 (https=)
WO (1) WO2020204161A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159915B1 (ko) * 2019-09-18 2020-09-24 주식회사 엑소코바이오 엑소좀 및/또는 세포외 소포체의 생성 촉진 방법
WO2022080461A1 (ja) * 2020-10-16 2022-04-21 富士フイルム和光純薬株式会社 細胞外小胞の産生用培地、培地キット、添加剤及び細胞外小胞の産生方法
CN112592892B (zh) * 2020-12-25 2022-04-22 新疆赛尔托马斯生物科技有限公司 一种诱导脐带间充质干细胞因子分泌的培养基及培养方法
US20250270564A1 (en) * 2021-10-11 2025-08-28 Theoria Science Inc. Extracellular vesicle secretion booster for boosting extracellular vesicle secretion, and use thereof
US11622949B1 (en) 2022-08-04 2023-04-11 Gad M. Gilad Agmatine compositions for treatment of osteoarthritis
JP7371975B1 (ja) 2022-09-27 2023-10-31 セルソース株式会社 細胞外小胞の製造方法及び細胞外小胞含有組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120150A1 (en) 2014-02-05 2015-08-13 Stc.Unm Exosomes as a therapeutic for cancer
WO2018182016A1 (ja) 2017-03-30 2018-10-04 日産化学株式会社 ナノファイバーを用いた細胞培養
WO2018225440A1 (ja) 2017-06-09 2018-12-13 国立大学法人大阪大学 拡張型心筋症治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047673A2 (en) * 2000-12-15 2002-06-20 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
AU2008311827A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
US20100189683A1 (en) * 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101662405B1 (ko) 2013-12-12 2016-10-05 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
WO2016167373A1 (ja) 2015-04-16 2016-10-20 日産化学工業株式会社 培地添加物及び培地組成物並びにそれらを用いた細胞又は組織の培養方法
EP3333254B1 (en) 2015-08-03 2025-05-14 Osaka University Mesenchymal stem cell-derived exosome
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
US20180133212A1 (en) * 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
EP4035659A1 (en) * 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
JP6981619B2 (ja) 2017-03-14 2021-12-15 株式会社ダイセル エクソソーム産生促進剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120150A1 (en) 2014-02-05 2015-08-13 Stc.Unm Exosomes as a therapeutic for cancer
WO2018182016A1 (ja) 2017-03-30 2018-10-04 日産化学株式会社 ナノファイバーを用いた細胞培養
WO2018225440A1 (ja) 2017-06-09 2018-12-13 国立大学法人大阪大学 拡張型心筋症治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
山下竜幸，他，硫酸化糖脂質サルファタイドによる間葉系幹細胞のエクソソーム分泌促進効果，日本再生医療学会雑誌 再生医療，2017年02月01日，第16巻／増刊号［通巻69号］，pp. 367, P-01-023

Also Published As

Publication number Publication date
EP3950060A4 (en) 2023-04-19
WO2020204161A1 (ja) 2020-10-08
US20220162561A1 (en) 2022-05-26
EP3950060A1 (en) 2022-02-09
JPWO2020204161A1 (https=) 2020-10-08

Similar Documents

Publication Publication Date Title
JP7508048B2 (ja) 細胞外小胞の分泌を促進するための組成物
AU2014386236B2 (en) Compositions of selenoorganic compounds and methods of use thereof
CN105142632A (zh) 通过投予尿石素或其前体增强自噬或增加寿命
EP4130014A1 (en) Deuterated oxophenylarsine compound and use thereof
WO2011158904A1 (ja) アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤
EP1583538A1 (fr) Utilisation de la 3-methoxy-pregnenolone pour la préparation d'un médicament destiné traiter les maladies neurodegeneratives
CA3055164A1 (en) Composition for inhibiting myofibrosis
KR20210102208A (ko) 신경계 질환의 치료
KR102566433B1 (ko) 커피 실버스킨 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 근육질환의 예방 또는 치료용 조성물
US20230241119A1 (en) Pharmaceutical composition for preventing or treating brain disease, comprising stem cell-derived exosome surface-modified with compound capable of binding to dopamine receptors or l-amino acid transporters
JP2026511977A (ja) Ｃｐｉ－４５５を含む幹細胞のアストロサイトへの分化誘導用組成物
ES2475211T3 (es) N-acetil-taurinato de cinc para su uso en un método de prevención y/o de tratamiento de enfermedades asociadas con la acumulación de lipofuscina
EP3595637A1 (en) Combination of active ingredients, compositions comprising it and their use in the treatment of sarcopenia
KR20040012396A (ko) 뇌신경성장인자 증강작용을 갖는 백강잠 추출물 및 이의활성성분을 함유하는 약학적 제제
KR102935226B1 (ko) 악액질 및 근손실의 예방 또는 치료용 조성물
CN119638607B (zh) 一种基于丁苯酞为载体的硫化物前药
JP2003335690A (ja) 受容体に親和性を有する組成物
KR20120023569A (ko) ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
JPWO2020138266A1 (ja) 細胞外小胞の分泌を抑制するための組成物
HK40064580A (en) Compositions of selenoorganic compounds and methods of use thereof
CN121793983A (zh) 化学诱导的重编程来逆转衰老
WO2025079163A1 (ja) ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｓ（＋）体
KR20160023965A (ko) 우르솔산 및 루신을 유효성분으로 함유하는 근육재생용 약학조성물
JP2024095271A (ja) 小胞体ストレス抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240610

R150 Certificate of patent or registration of utility model

Ref document number: 7508048

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150